Broad inhibition of kinases of the ERBB family by neratinib has been shown to suppress KRAS G12D mutant-driven lung tumors and enhance the potency of MEK inhibition by trametinib in a cre-inducible immunocompetent mouse model of autochthonous lung cancer [20]. Here, KRAS is linked to lung carcinoma.